Status:
COMPLETED
Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To assess the initial pharmacokinetic profile of single doses of 25mg and 50 mg of DVS SR to healthy subjects.
Eligibility Criteria
Inclusion
- Men or non-pregnant, non-lactating women
- Body mass index 18 - 30 kg/m2
- Body weight greater than or equal to 60kg
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00440427
Start Date
February 1 2007
End Date
February 1 2007
Last Update
December 5 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston, Massachusetts, United States, 02135